135311-97-6

Basic information

• Product Name: 8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride
• Synonyms: 8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride;8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride/ 6,7-dihydroisoquinolin-8(5H)-one hydrochloride;6,7-Dihydro-5H-isoquinolin-8-one hydrochloride
• CAS NO: 135311-97-6
• Molecular Formula: C₉H₉NO*ClH
• Molecular Weight: 183.6348
• Mol File: 135311-97-6.mol
• Article Data: 1

Chemical Properties

• Melting Point: 227-229 °C
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride(135311-97-6)
• EPA Substance Registry System: 8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride(135311-97-6)

Safety Data

• Hazardous Substances Data: 135311-97-6(Hazardous Substances Data)

Usage

General Description

8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride is a chemical compound that belongs to the class of isoquinolinone derivatives. It is commonly used in the synthesis of organic compounds and pharmaceuticals. The hydrochloride salt form of this compound is often utilized in the manufacturing of drugs as it can enhance the stability and solubility of the active ingredient. Additionally, it has been studied for its potential pharmacological properties, such as anti-inflammatory and analgesic effects. Due to its versatile applications, 8(5H)-Isoquinolinone, 6,7-dihydro-, hydrochloride is an important chemical in the field of medicinal chemistry and drug development.

Upstream product

• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 

Relevant articles and documents

Synthesis, optical resolution, absolute configuration, and preliminary pharmacology of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo- [3,2-h]isoquinoline, a structural analog of nicotine

Title compound, 8, has been synthesized from isoquinolinone, 1 (an improved preparation for which is presented) and separated into its antipodes with D- and L-di-p-toluoyltartaric acids. These antipodes and the racemic precursor have been evaluated (and found active) in two in vivo systems for their effects. The most potent of the three, (+)-8, has an ED50 of 7.13 μmol/kg for inhibition of spontaneous activity and 7.45 μmol/kg for antinociception compared to 4.44 and 4.81 μmol/kg, respectively, for (S)-(- )-nicotine. Compounds (-)-8 and 7 are about one-fourth as potent. Isomer (+)- 8 has the 3aR,9bS configuration, the latter corresponding to (S)-(-)-nicotine as determined by X-ray crystallography. However, (+)-8 failed to compete for [3H]-nicotine binding, and its pharmacological effects were not blocked by mecamylamine. These bridged nicotine analogs either are binding to an as- yet-unidentified nicotinic receptor or they represent a novel class of non- nicotinic analgesics.